News

Six months to go until the revised Data Protection Act comes into force on September 1, 2023. Do you have an up-to-date data protection declaration? Do you know how to respond to a request for information? Have you outsourced services to third-party companies that process personal data on your behalf? Have you defined a process for reporting data security breaches (such as loss, deletion, or modification of personal data due to hacker attacks, etc.)?

Prepare yourself for the new requirements. Our data protection expert, attorney-at-law Fabiola Weilenmann, together with the entire BGPartner team, will be happy to advise and support you in implementing the new requirements.

Another VisMootCourt Trial Round in the books! This time we had the privilege of hosting the teams of Universität Bern and Université de Genève who did an outstanding job with their pleadings.

BGPartner continues to be impressed with the determination and investment these students are willing to put in. It clearly pays off, as their performances were excellent. You have done a fantastic job. 
 
Find out in the After Movie what the students benefited most from, how realistic a trial round is, what the preparation looks like and why BGPartner continues to support this project. Enjoy watching.

BGPartner keeps its know-how in construction and planning law up to date. Our team, represented by Olivier Bula and Maja Rasovic, attended the Construction Law Conference in Freiburg.

The Construction Law Conference of the University of Freiburg is one of the most important and renowned Swiss events and a must for every construction lawyer. Every two years, numerous experts from the areas of law, economics, public administration and construction practice meet at the University of Freiburg to discuss the latest issues in private and public construction law.

Would you like to learn more about our law expertise? Please klick here.

SynAct Pharma AB, a Swedish listed biotechnology company (Nasdaq Stockholm: SYNACT), acquires 100% of TXP Pharma AG, a privately owned Swiss biotech company, researching and developing pharmaceutical drugs for the treatment of autoimmune and inflammatory diseases. BGPartner assisted SynAct Pharma AB in the negotiations and advised on all Swiss legal matters regarding this international M&A transaction.  

Through the acquisition of TXP Pharma AG, SynAct Pharma AB’s position as a leader within therapies for resolution treatment through melanocortin biology is strengthened. The acquisition gives SynAct Pharma AB two platforms that complement each other and create a versatility to develop therapies to address the full range of inflammatory and autoimmune diseases. The development portfolio is strengthened, and the aim is that SynAct Pharma AB will shortly have two projects in clinical development and another two in a relatively advanced preclinical phase.

The purchase price consisted of a fixed purchase price of approximately SEK 136 million (approximate CHF 12 million) and a conditional additional purchase price of SEK 55 million (approximate CHF 5 million). The fixed purchase price has been paid through newly issued shares in SynAct Pharma AB.

The team of BGPartner was led by Oliver Gnehm (Partner) and further consisted of Alain P. Röthlisberger (Partner) and Victoria Marty (Associate).

More information about our negotiation expertise can be found here. The press release of SynAct Pharma AB can be found here.

BGPartner is pleased to welcome Louis Moser (Substitut) to the Berne team as of January 1, 2023. Further information on Louis Moser and our entire team can be found here.